menu
    • menu
    [{"orgOrder":0,"company":"Context Therapeutics","sponsor":"The Menarini Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"Onapristone","moa":"||PR","graph1":"Oncology","graph2":"Phase II","graph3":"Context Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Context Therapeutics \/ The Menarini Group","highestDevelopmentStatusID":"8","companyTruncated":"Context Therapeutics \/ The Menarini Group"},{"orgOrder":0,"company":"Context Therapeutics","sponsor":"Nextech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Private Placement","leadProduct":"CTIM-76","moa":"CLDN6\/CD3","graph1":"Oncology","graph2":"Preclinical","graph3":"Context Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Context Therapeutics \/ Nextech","highestDevelopmentStatusID":"4","companyTruncated":"Context Therapeutics \/ Nextech"},{"orgOrder":0,"company":"Context Therapeutics","sponsor":"Lonza Inc & Lonza America Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Agreement","leadProduct":"CTIM-76","moa":"CLDN6\/CD3","graph1":"Oncology","graph2":"Preclinical","graph3":"Context Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Context Therapeutics \/ Lonza Inc & Lonza America Inc","highestDevelopmentStatusID":"4","companyTruncated":"Context Therapeutics \/ Lonza Inc & Lonza America Inc"},{"orgOrder":0,"company":"Context Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"CTIM-76","moa":"CLDN6\/CD3","graph1":"Oncology","graph2":"IND Enabling","graph3":"Context Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Context Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Context Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Context Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"CTIM-76","moa":"CLDN6\/CD3","graph1":"Oncology","graph2":"IND Enabling","graph3":"Context Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Context Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Context Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Context Therapeutics","sponsor":"Integral Molecular","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"CTIM-76","moa":"CLDN6\/CD3","graph1":"Oncology","graph2":"Preclinical","graph3":"Context Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Context Therapeutics \/ Integral Molecular","highestDevelopmentStatusID":"4","companyTruncated":"Context Therapeutics \/ Integral Molecular"},{"orgOrder":0,"company":"Context Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"CTIM-76","moa":"CLDN6\/CD3","graph1":"Oncology","graph2":"IND Enabling","graph3":"Context Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Context Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Context Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Context Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Onapristone","moa":"PR","graph1":"Oncology","graph2":"Phase II","graph3":"Context Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Context Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Context Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Context Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Onapristone","moa":"PR","graph1":"Oncology","graph2":"Phase II","graph3":"Context Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Context Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Context Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Context Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Onapristone","moa":"||PR","graph1":"Oncology","graph2":"Phase II","graph3":"Context Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Context Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Context Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Context Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Onapristone","moa":"||PR","graph1":"Oncology","graph2":"Phase II","graph3":"Context Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Context Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Context Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Context Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Onapristone","moa":"||PR","graph1":"Oncology","graph2":"Phase II","graph3":"Context Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Context Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Context Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Context Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Onapristone","moa":"PR","graph1":"Oncology","graph2":"Phase II","graph3":"Context Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Context Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Context Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Context Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Onapristone","moa":"||PR","graph1":"Oncology","graph2":"Phase II","graph3":"Context Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Context Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Context Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Context Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Onapristone","moa":"PR","graph1":"Oncology","graph2":"Phase II","graph3":"Context Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Context Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Context Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Context Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"CTIM-76","moa":"CLDN6\/CD3","graph1":"Oncology","graph2":"Phase I","graph3":"Context Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Context Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Context Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Context Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"CTIM-76","moa":"CLDN6\/CD3","graph1":"Oncology","graph2":"Phase I","graph3":"Context Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Context Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Context Therapeutics \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Context Therapeutics

    Menu

    Context Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
    filter

    Year

    filter

    DEALS // DEV.

    filter

    Country

    filter
    Sponsor
    filter

    Therapeutic Area

    filter

    Study Phase

    filter

    Deal Type

    filter

    Product Type

    filter

    Dosage Form

    filter

    Lead Product

    filter

    Target

    refresh Filters
    refresh Reset Filter
    refresh Reset Filter
    price-trend All Developments

    Therapeutic Area by Lead Product

    ForexGraph

    Study Phase by Lead Product

    ForexGraph

    Company by Lead Product

    ForexGraph

    Top Deals by Deal Size (USD bn)

    ForexGraph

    01

    Context Therapeutics

    U.S.A arrow
    Interphex
    Not Confirmed

    Context Therapeutics

    U.S.A arrow
    Interphex
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : CTIM-76

    Therapeutic Area : Oncology

    Study Phase : Phase I

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Integral’s Out-Licensed Bispecific Antibody Enters Solid Tumor Trial

    Details : CTIM-76 is an anti-Claudin 6 (CLDN6) bispecific antibody, which is currently being evaluated for the treatment of platinum-refractory/resistant ovarian cancer.

    Product Name : CTIM-76

    Product Type : Antibody

    Upfront Cash : Inapplicable

    March 06, 2025

    Lead Product(s) : CTIM-76

    Therapeutic Area : Oncology

    Highest Development Status : Phase I

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    02

    Context Therapeutics

    U.S.A arrow
    Interphex
    Not Confirmed

    Context Therapeutics

    U.S.A arrow
    Interphex
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : CTIM-76

    Therapeutic Area : Oncology

    Study Phase : Phase I

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Context Therapeutics Doses First Patient in Phase 1 Trial of CTIM-76

    Details : CTIM-76 is a CLDN6 x CD3 T cell engaging bispecific antibody. It is being evaluated for the treatment of Claudin 6-Positive gynecologic and testicular cancers.

    Product Name : CTIM-76

    Product Type : Antibody

    Upfront Cash : Inapplicable

    January 14, 2025

    Lead Product(s) : CTIM-76

    Therapeutic Area : Oncology

    Highest Development Status : Phase I

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    03

    Context Therapeutics

    U.S.A arrow
    Peptide-Based Therapeutics Summit
    Not Confirmed

    Context Therapeutics

    U.S.A arrow
    Peptide-Based Therapeutics Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : CTIM-76

    Therapeutic Area : Oncology

    Study Phase : Preclinical

    Sponsor : Nextech

    Deal Size : $100.0 million

    Deal Type : Private Placement

    DEALS_DEV arrow-down

    Context Therapeutics Announces $100 Million Private Placement

    Details : The net proceeds will be used to fund the clinical development of CTIM-76, under early-stage trials for CLDN6-positive ovarian, lung, and testicular tumors.

    Product Name : CTIM-76

    Product Type : Antibody

    Upfront Cash : Undisclosed

    February 05, 2024

    Lead Product(s) : CTIM-76

    Therapeutic Area : Oncology

    Highest Development Status : Preclinical

    Sponsor : Nextech

    Deal Size : $100.0 million

    Deal Type : Private Placement

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    04

    Context Therapeutics

    U.S.A arrow
    Interphex
    Not Confirmed

    Context Therapeutics

    U.S.A arrow
    Interphex
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : CTIM-76

    Therapeutic Area : Oncology

    Study Phase : IND Enabling

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Context Therapeutics Announces FDA Clearance of IND for Phase 1 Trial of CTIM-76

    Details : CTIM-76 is a Claudin 6 x CD3 T cell engaging bispecific antibody, which is currently being evaluated for the treatment of patients with CLDN6-positive gynecologic and testicular cancers.

    Product Name : CTIM-76

    Product Type : Antibody

    Upfront Cash : Inapplicable

    February 05, 2024

    Lead Product(s) : CTIM-76

    Therapeutic Area : Oncology

    Highest Development Status : IND Enabling

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    05

    Context Therapeutics

    U.S.A arrow
    Interphex
    Not Confirmed

    Context Therapeutics

    U.S.A arrow
    Interphex
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : CTIM-76

    Therapeutic Area : Oncology

    Study Phase : IND Enabling

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Context Submits IND Application to Evaluate CTIM-76 in Claudin 6-Positive Cancers

    Details : CTIM-76 is a CLDN6 x CD3 T cell engaging bispecific antibody. It is being evaluated for the treatment of Claudin 6-Positive gynecologic and testicular cancers.

    Product Name : CTIM-76

    Product Type : Antibody

    Upfront Cash : Inapplicable

    January 04, 2024

    Lead Product(s) : CTIM-76

    Therapeutic Area : Oncology

    Highest Development Status : IND Enabling

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    06

    Context Therapeutics

    U.S.A arrow
    Interphex
    Not Confirmed

    Context Therapeutics

    U.S.A arrow
    Interphex
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : CTIM-76

    Therapeutic Area : Oncology

    Study Phase : IND Enabling

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Context Therapeutics Announces Preclinical Data Demonstrating Differentiated and Active Profile of its Claudin...

    Details : CTIM-76, is a CLDN6 x CD3 bispecific antibody that incorporates a highly selective CLDN6 binding arm and a CD3 binding single-chain Fv domain in an IgG format. It is is potent with specific lysis of CLDN6+ cancer cells over normal cells.

    Product Name : CTIM-76

    Product Type : Antibody

    Upfront Cash : Inapplicable

    October 31, 2023

    Lead Product(s) : CTIM-76

    Therapeutic Area : Oncology

    Highest Development Status : IND Enabling

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    07

    Context Therapeutics

    U.S.A arrow
    Interphex
    Not Confirmed

    Context Therapeutics

    U.S.A arrow
    Interphex
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : CTIM-76

    Therapeutic Area : Oncology

    Study Phase : Preclinical

    Sponsor : Lonza Inc & Lonza America Inc

    Deal Size : Undisclosed

    Deal Type : Agreement

    DEALS_DEV arrow-down

    Context Therapeutics and Lonza Enter Manufacturing Agreement for Bispecific Antibody Targeting Claudin 6-Posit...

    Details : Under the agreement, Lonza will support the development and manufacturing of CTIM-76, a CLDN6 x CD3 bispecific antibody clinical candidate. The bispecific antibody-based therapy is being developed to redirect T-cell mediated lysis toward malignant cells ...

    Product Name : CTIM-76

    Product Type : Antibody

    Upfront Cash : Undisclosed

    September 01, 2023

    Lead Product(s) : CTIM-76

    Therapeutic Area : Oncology

    Highest Development Status : Preclinical

    Sponsor : Lonza Inc & Lonza America Inc

    Deal Size : Undisclosed

    Deal Type : Agreement

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    08

    Context Therapeutics

    U.S.A arrow
    Interphex
    Not Confirmed

    Context Therapeutics

    U.S.A arrow
    Interphex
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Onapristone,Anastrozole

    Therapeutic Area : Oncology

    Study Phase : Phase II

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Context Therapeutics Highlights Clinical Responses from the Phase 2 OATH Clinical Trial Evaluating ONA-XR for ...

    Details : ONA-XR (onapristone) is a selective progesterone receptor (PR) antagonist designed to block both ligand dependent and ligand-independent activity of PR which downregulates cancer stem cellmobilization, and blocking immune evasion.

    Product Name : ONA-XR

    Product Type : Other Small Molecule

    Upfront Cash : Inapplicable

    June 02, 2023

    Lead Product(s) : Onapristone,Anastrozole

    Therapeutic Area : Oncology

    Highest Development Status : Phase II

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    09

    Context Therapeutics

    U.S.A arrow
    Interphex
    Not Confirmed

    Context Therapeutics

    U.S.A arrow
    Interphex
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : CTIM-76

    Therapeutic Area : Oncology

    Study Phase : Preclinical

    Sponsor : Integral Molecular

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Context Therapeutics® Nominates CTIM-76 Bispecific Antibody Candidate to Develop Treatment for Claudin 6-Posi...

    Details : CTIM-76, a T cell-engaging bispecific antibody, as its lead clinical development candidate to target Claudin 6 (CLDN6) positive cancers.

    Product Name : CTIM-76

    Product Type : Antibody

    Upfront Cash : Inapplicable

    November 29, 2022

    Lead Product(s) : CTIM-76

    Therapeutic Area : Oncology

    Highest Development Status : Preclinical

    Sponsor : Integral Molecular

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    10

    Context Therapeutics

    U.S.A arrow
    Interphex
    Not Confirmed

    Context Therapeutics

    U.S.A arrow
    Interphex
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Onapristone,Fulvestrant

    Therapeutic Area : Oncology

    Study Phase : Phase II

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Context Therapeutics® Announces Clinical Updates on ONA-XR to be Presented at 2022 San Antonio Breast Cancer ...

    Details : ONA-XR (onapristone extended release) is a potent and specific antagonist of the progesterone receptor (PR) that is orally administered. Preclinical and clinical data suggest that ONA-XR has anticancer activity by inhibiting progesterone receptor binding...

    Product Name : ONA-XR

    Product Type : Other Small Molecule

    Upfront Cash : Inapplicable

    November 21, 2022

    Lead Product(s) : Onapristone,Fulvestrant

    Therapeutic Area : Oncology

    Highest Development Status : Phase II

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth